Laboratory Data Sample Clauses

Laboratory Data. Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis will be taken at the times indicated in the Study Plan at the time points described in section 6.4.5 of the Clinical Study Protocol. The baseline value of each laboratory variable will be derived, as described in the Clinical Study Protocol, values captured 3 days before baseline visit will be considered as baseline value. If multiple records are present between -3 days and baseline visit then last value obtained prior to the first dose of medication will be considered as baseline. Alternatively, if two visits are equally eligible to assess patient status at baseline (e.g., two assessment at screening or baseline both prior to first dose with no w ashout or other intervention in the screening period), the average can be taken as a baseline value. The other post-baseline assessment non missing value lab parameter closest to the scheduled visit date, will be considered as visit value. The visit will be missing if no assessment was reported within the specified visit window around the scheduled date. If two assessments are equidistant from a scheduled visit, then the earlier of the two will be used. Designation of visits for Lab data assessment are given in table below intermittent dosing schedule (2/5) (Table 3a) Table 3a Day Ranges for LAB assessments Cycle No. Visit day Target day Day Range Screening -1 -28 – -1 1 Day 1 (Baseline) 1 1 1 Day 2 2 2 1 Day 3 3 3 - 6 1 Day 9 9 7 – 12 1 Day 16 16 13 – 19 1 Day 23 23 20 – 26 2 Day 2 30 27 – 33 2 Day 8 36 34 – 39 2 Day 15 43 40 – 46 2 Day 22 50 47 – 54 3 Day 2 58 55 – 72 4 Day 2 86 73 – 100 Y Day 2 X X-13 – X+14 Where Y = 5,6, …. And X=(Y-1)*28+2 Designation of visits for Lab data assessment are given in table below for intermittent dosing schedule (4/3) (Table 3b) Table 3b Day Ranges for LAB assessments Cycle No. Visit day Target day Day Range Screening -1 -28 – -1 1 Day 1 (Baseline) 1 -3 – 1 1 Day 2 2 2 – 3 1 Day 5 5 4 – 7 1 Day 9 9 8 – 12 1 Day 16 16 13 – 19 1 Day 23 23 20 – 26 2 Day 2 30 27 – 33 2 Day 8 36 34 – 39 Table 3b Day Ranges for LAB assessments Cycle No. Visit day Target day Day Range 2 Day 15 43 40 – 46 2 Day 22 50 47 – 54 3 Day 2 58 55 – 72 4 Day 2 86 73 – 100 Y Day 2 X X-13 – X+14 Where y = 5,6, …. And X=(Y-1)*28+2 For Serum/Plasma Glucose, Insulin and Insulin c-peptide measurement a visit window rules are defined in table 3c and 3d for respective dosing cohorts. Table 3c Day Ranges for Serum/Plasma Glucose...
AutoNDA by SimpleDocs
Laboratory Data. The Laboratory QA Reviewers will be responsible for validation of laboratory project implementation measures of success. The QA Reviewer will be responsible for the submittal of data packages to the Project Manager to support the quality management plans in Appendix B and Appendix C.
Laboratory Data. Laboratory data will be transferred electronically as described in Section 2.9.4. Once received, the data will be uploaded into the Consultant’s database, which uses Microsoft SQL 2000 software or equivalent. The data are tracked in the database using both laboratories identifiers and the sampling point labels.
Laboratory Data 

Related to Laboratory Data

  • Product Data Illustrations, standard schedules, performance charts, instructions, brochures, diagrams, and other information furnished by Developer to illustrate a material, product, or system for some portion of the Work.

  • Licensed Technology The term “Licensed Technology” shall mean the Licensed Patent Rights, Licensed Know-How and Licensed Biological Materials.

  • Licensee Data Licensee acknowledges and agrees that Licensee will be solely responsible for backing-up, and taking all appropriate measures to protect and secure, Licensee Data. Licensee acknowledges that Nuix may make, store and maintain back up copies of Licensee Data, but is not obliged to do so. Nuix will not be liable for any loss or corruption of Licensee Data.

  • Third Party Materials The Application may display, include, or make available third-party content (including data, information, applications, and other products, services, and/or materials) or provide links to third-party websites or services, including through third- party advertising ("Third-Party Materials"). You acknowledge and agree that Company is not responsible for Third-Party Materials, including their accuracy, completeness, timeliness, validity, copyright compliance, legality, decency, quality, or any other aspect thereof. Company does not assume and will not have any liability or responsibility to you or any other person or entity for any Third-Party Materials. Third-Party Materials and links thereto are provided solely as a convenience to you, and you access and use them entirely at your own risk and subject to such third parties' terms and conditions.

  • Laboratory a. Drug tests shall be conducted by laboratories licensed and approved by SAMSHA which comply with the American Occupational Medical Association (AOMA) ethical standards. Upon advance notice, the parties retain the right to inspect the laboratory to determine conformity with the standards described in this policy. The laboratory will only test for drugs identified in this policy. The City shall bear the cost of all required testing unless otherwise specified herein.

  • Regulatory Materials (a) Alvogen shall have the sole right to control filing or submission of Regulatory Materials with the Regulatory Agencies in the Territory with respect to Product including the MAA Approval for Product and Regulatory Approvals in the Territory, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. shall be responsible for managing all communications and interactions with the Regulatory Agencies in the Territory with respect to Product in the Territory. In all cases, prior to the filing of any Regulatory Materials (including the MAA for Product) for Product with the applicable Regulatory Agency, Alvogen shall provide a copy thereof to Pfenex (through the Executive Steering Committee) for its review and comment. Pfenex shall have fifteen (15) Business Days from the date it receives a copy of any Regulatory Materials with respect to the Product to provide Alvogen with comments regarding such Regulatory Materials, unless the Regulatory Agencies in the Territory or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not reasonably permit such advanced notice, in which case Pfenex shall have as much time as is reasonably practicable to provide Alvogen with comments. Alvogen shall consider all such comments in good faith. Alvogen shall, to the extent permitted by Applicable Law, provide Pfenex with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of Alvogen or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with the Regulatory Agencies in the Territory with respect to Product, and in any case keep Pfenex informed as to all material interactions with the Regulatory Agencies in the Territory with respect to Product, and (iii) a copy of any material documents, information and correspondence submitted to or received from the Regulatory Agencies in the Territory with respect to Product as soon as reasonably practicable.

  • Technical Information The Employer agrees to provide to the Union such information that is available relating to employees in the bargaining unit, as may be required by the Union for collective bargaining purposes.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Licensed Materials The materials that are the subject of this Agreement are set forth in Appendix A ("Licensed Materials").

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

Time is Money Join Law Insider Premium to draft better contracts faster.